Specifically Targeting Interleukin-13 with Tralokinumab Improved Sleep in Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Trials in Patients with Atopic Dermatitis

Main Article Content

Jonathan Silverberg
Department of Dermatology, The George Washington University School of Medicine and Health Sciences, Washington, DC, USA

Sebastien Barbarot
Department of Dermatology, CHU, Nantes, France

Melinda Gooderham
SKiN Centre for Dermatology, Peterborough, Ontario, Canada

Jan Simon
Department of Dermatology, Venereology and Allergology, University Medical Center, Leipzig, Germany

Eric Simpson
Department of Dermatology, Oregon Health & Science University, Portland, OR, USA

Azra Kurbasic
LEO Pharma A/S, Ballerup, Denmark

Christina Olsen
LEO Pharma A/S, Ballerup, Denmark

Michael Cork
Sheffield Dermatology Research, Department of Infection, Immunity and Cardiovascular Disease, The University of Sheffield, Sheffield, UK

Keywords

Atopic Dermatitis, Biologic, Tralokinumab, IL-13, Sleep

Abstract

Abstract not available.

References

1. Weidinger S, Novak N. Lancet 2016; 387: 1109–1122.

2. Silverberg JI et al. Ann Allergy Asthma Immunol 2018; 121: 340–347.

3. Dalgard FJ et al. J Invest Dermatol 2015; 135: 984–991.

4. Chang Y, Chiang B. J Allergy Clin Immunol 2018; 142: 1033−1040.

5. Silverberg JI et al. J Invest Dermatol 2015; 135: 56−66.

6. Jeon C et al. Dermatol Ther (Heidelb) 2017;

7: 249−264. 7. Bieber T. Allergy 2020; 75: 54−62.

8. Tsoi LC et al. J Invest Dermatol 2019; 139: 1480−1489.

9. Popovic B et al. J Mol Biol 2017; 429: 208−219.

10. Simpson E et al. Presented at the American Academy of Dermatology Annual Meeting, March 20–24, 2020, Denver, CO, USA. 11. Lei D et al. Ann Allergy Asthma Immunol 2020; 124: 261−266.

Article Sidebar

Poster PDF
Published
Jan 1, 2021
DOI https://doi.org/10.25251/skin.5.supp.9

Article Details

How to Cite
[1]
Silverberg, J., Barbarot, S., Gooderham, M., Simon, J., Simpson, E., Kurbasic, A., Olsen, C. and Cork, M. 2021. Specifically Targeting Interleukin-13 with Tralokinumab Improved Sleep in Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Trials in Patients with Atopic Dermatitis. SKIN The Journal of Cutaneous Medicine. 5, 1 (Jan. 2021), s9. DOI:https://doi.org/10.25251/skin.5.supp.9.
Issue
Vol. 5 No. 1 (2021): January Issue & Poster Presentations (WC21 Dermatology Conference®)
Section
Atopic Dermatitis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>